M A Socinski

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Gemcitabine-based combinations as preoperative therapy in resectable non-small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599 7305, USA
    Clin Lung Cancer 4:S50-5. 2003
  2. ncbi request reprint Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 2:S26-33. 2001
  3. ncbi request reprint Irinotecan in non-small-cell lung cancer: status of ongoing trials
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC e mail
    Clin Lung Cancer 4:S15-20. 2002
  4. ncbi request reprint Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Drugs Today (Barc) 44:293-301. 2008
  5. doi request reprint Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial
    Mark A Socinski
    University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1308-16. 2008
  6. ncbi request reprint A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:852-61. 2010
  7. ncbi request reprint The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 33:S32-8. 2006
  8. ncbi request reprint Adjuvant therapy of resected non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 6:162-9. 2004
  9. doi request reprint A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
    M A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 20:1068-73. 2009
  10. ncbi request reprint Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:4341-50. 2004

Collaborators

Detail Information

Publications99

  1. ncbi request reprint Gemcitabine-based combinations as preoperative therapy in resectable non-small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599 7305, USA
    Clin Lung Cancer 4:S50-5. 2003
    ..Continued evaluation of gemcitabine-containing regimens as preoperative therapy is warranted given their level of activity and tolerability in advanced NSCLC...
  2. ncbi request reprint Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 2:S26-33. 2001
    ..The combination shows appreciable activity, and survival data are favorable, warranting further study of this regimen. A review of other irinotecan-containing triplet combinations is presented...
  3. ncbi request reprint Irinotecan in non-small-cell lung cancer: status of ongoing trials
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC e mail
    Clin Lung Cancer 4:S15-20. 2002
    ..Future trials should focus on the integration of the new targeted agents in combination with irinotecan-containing regimens in all stages of NSCLC...
  4. ncbi request reprint Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Drugs Today (Barc) 44:293-301. 2008
    ..Bevacizumab is the first targeted therapeutic agent to improve survival in advanced NSCLC when added to standard chemotherapeutic regimens...
  5. doi request reprint Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial
    Mark A Socinski
    University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1308-16. 2008
    ..We undertook a phase II trial to assess the efficacy and safety of single-agent pemetrexed (P) in relapsed small-cell lung cancer (SCLC) patients...
  6. ncbi request reprint A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:852-61. 2010
    ..This nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and weekly nab-paclitaxel plus q3w carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) for a phase 3 trial...
  7. ncbi request reprint The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 33:S32-8. 2006
    ....
  8. ncbi request reprint Adjuvant therapy of resected non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 6:162-9. 2004
    ..Currently, the totality of the data supports a discussion with patients with resected NSCLC regarding the potential benefits of adjuvant therapy...
  9. doi request reprint A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
    M A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 20:1068-73. 2009
    ..This trial investigated the efficacy and safety of weekly cetuximab combined with two different schedules of paclitaxel/carboplatin for stage IIIB/IV non-small-cell lung cancer (NSCLC)...
  10. ncbi request reprint Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:4341-50. 2004
    ..Dose escalation using three-dimensional thoracic conformal radiation therapy (TCRT) is one strategy to improve local control and perhaps survival...
  11. doi request reprint The current status and evolving role of sunitinib in non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:S119-23. 2008
    ..Results of these trials are eagerly awaited and will help define the role of sunitinib in the therapeutic approach to NSCLC...
  12. doi request reprint Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC 27599, USA
    J Clin Oncol 26:2457-63. 2008
    ..To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC)...
  13. ncbi request reprint Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, Chapel Hill 27599, USA
    J Clin Oncol 24:4840-7. 2006
    ....
  14. ncbi request reprint Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 13:s4597-601. 2007
    ..The lack of a biomarker to identify a subset of NSCLC patients who may derive benefit from this agent limits any potential enthusiasm for further trials of panitumumab at this time in NSCLC...
  15. ncbi request reprint Limited-stage small-cell lung cancer: the current status of combined-modality therapy
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:4137-45. 2007
    ..LS-SCLC has been a model cancer in terms of the potential benefit of combined chemoradiotherapy strategies in improving patient outcomes...
  16. ncbi request reprint Seeking new options for the treatment of small-cell lung cancer
    M A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 50:S25-6. 2005
    ..Observations from this trial will help to define the future role of pemetrexed in SCLC...
  17. ncbi request reprint A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 17:104-9. 2006
    ..The optimal schedule of taxane administration has been an area of active interest in several recent clinical trials...
  18. ncbi request reprint Duration of therapy in advanced, metastatic non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Clin Adv Hematol Oncol 1:33-8. 2003
    ..Prolonged therapy does not appear to improve survival and carries the risk of cumulative toxicity. Second-line therapy considered in those patients fit enough to receive it at the time of disease progression...
  19. pmc Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  20. ncbi request reprint Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of South Carolina, 101 Manning Drive, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S114-8. 2005
    ..In addition, a change in the therapeutic platform is planned that explores a full-dose systemic approach with the antifolate pemetrexed that possesses radiosensitizing properties...
  21. ncbi request reprint Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of South Carolina, 101 Manning Drive, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S18-24. 2005
    ..Future aggressive approaches must enhance both locoregional and distant control of occult disease, with acceptable rates of both acute and long-term toxicities...
  22. ncbi request reprint Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Clin Cancer Res 10:4210s-4214s. 2004
    ..Future research may improve outcomes through identifying prognostic markers of treatment response to both standard cytotoxic and newer "targeted" therapies...
  23. ncbi request reprint Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
    M A Socinski
    Cancer and Leukemia Group B, Chicago, IL, USA
    Ann Oncol 15:1033-41. 2004
    ..Combined modality therapy (CMT) is the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC); however, insufficient data are available regarding prognostic factors in this disease setting...
  24. doi request reprint Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 27:4787-92. 2009
    ....
  25. doi request reprint Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 5:1963-9. 2010
    ..This trial assessed pemetrexed-carboplatin ± enzastaurin to docetaxel-carboplatin in advanced non-small cell lung cancer...
  26. ncbi request reprint Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
    ..This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC)...
  27. ncbi request reprint Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Cancer 95:1265-73. 2002
    ..The authors sought to determine the activity of second-line, low-dose, weekly paclitaxel in patients with NSCLC who failed first-line chemotherapy with carboplatin plus paclitaxel...
  28. ncbi request reprint Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 20:1335-43. 2002
    ..To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC)...
  29. ncbi request reprint Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599, USA
    Cancer 92:1213-23. 2001
    ..The dose of thoracic conformal radiation therapy (TCRT) from 60 to 74 gray (Gy) was increased. Endpoints included response rate, toxicity, and survival...
  30. doi request reprint Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer
    Mark A Socinski
    University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Cancer Treat Rev 37:611-7. 2011
    ..g., sorafenib, sunitinib) and triple (e.g., BIBF 1120, pazopanib) antiangiogenic tyrosine kinase inhibitors currently in development for the treatment of non-small cell lung cancer...
  31. ncbi request reprint Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium
    M A Socinski
    Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, USA
    Oncologist 6:20-4. 2001
    ..Key morbidity observed thus far has involved the esophagus. Further cohorts of patients will receive higher doses of conformal radiotherapy (in 6.4 Gy increments) until the maximum tolerated dose is reached...
  32. ncbi request reprint Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 19:1078-87. 2001
    ..To determine the maximum-tolerated dose, toxicities, and dose suitable for phase II/III trials of irinotecan (CPT-11) combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer (NSCLC)...
  33. ncbi request reprint Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer
    M A Socinski
    The Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill 27599, USA
    Oncologist 4:408-16. 1999
    ..Given the overall activity and impact on survival along with an acceptable toxicity profile, single-agent paclitaxel warrants comparison to other active agents and combination regimens in advanced, metastatic NSCLC...
  34. ncbi request reprint Chemotherapeutic management of stage IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, CB 7305, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Chest 123:226S-243S. 2003
    ..In addition, this awareness will allow them to make referrals, when appropriate, to physicians who are trained in the administration of chemotherapy and the management of patients undergoing such therapy...
  35. ncbi request reprint Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and US Oncology, Houston, TX, USA
    Lung Cancer 40:91-7. 2003
    ..This regimen has a tolerable toxicity profile and a favorable and convenient administration schedule...
  36. doi request reprint Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:5255-61. 2009
    ..This phase II trial, AVF3752g (PASSPORT), specifically addressed bevacizumab safety (incidence of grade > or = 2 CNS hemorrhage) in patients with NSCLC and previously treated brain metastases...
  37. ncbi request reprint Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599 7305, USA
    Clin Lung Cancer 5:274-89. 2004
    ..Trials under way will determine the future of adjuvant or induction chemotherapy in treating this patient population...
  38. doi request reprint Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:354-60. 2010
    ....
  39. ncbi request reprint The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, CB 7305, 3009 Old Clinic Building, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Respir Care Clin N Am 9:207-36. 2003
    ..It is only through the successful and timely completion of well-designed clinical trials that we will advance our knowledge of improved treatment options for our patients with this disease...
  40. ncbi request reprint Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    Chest 132:277S-289S. 2007
    ..Stage IV non-small cell lung cancer (NSCLC) remains a treatable but incurable disease...
  41. doi request reprint The emerging role of biomarkers in advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 11:149-59. 2010
    ..Further assessment of these and other novel biomarkers is warranted to help define which patients with advanced NSCLC may derive the most benefit from targeted therapies...
  42. doi request reprint Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
    Jean Yves Douillard
    M D Anderson Cancer Center, Thoracic Head and Neck Medical Oncology, Box 432, 1515 Holcombe Blvd, Houston, TX 77401, USA
    J Clin Oncol 28:744-52. 2010
    ....
  43. ncbi request reprint Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer
    Thomas A Hensing
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Lung Cancer 47:253-9. 2005
    ..Factors increasing the likelihood of second-line therapy include high performance status, female gender and non-squamous histology, while early termination of first-line therapy decreased the likelihood of further therapy...
  44. doi request reprint Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance
    Jyoti D Patel
    Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Lung Cancer 10:252-6. 2009
    ....
  45. ncbi request reprint The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel
    Thomas A Hensing
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer 98:779-88. 2003
    ....
  46. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  47. ncbi request reprint Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium
    Lawrence B Marks
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 22:4329-40. 2004
    ..6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N)...
  48. ncbi request reprint Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
    M A Socinski
    University of North Carolina at Chapel Hill, Chapel Hill, NC Wake Forest University, Winston Salem, NC
    J Clin Oncol 26:7517. 2008
    ..7517 Background: Therapies directed at both the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways have been shown to improve survival in NSCLC and also have radiosensitizing properties...
  49. ncbi request reprint Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill 27599 7305, USA
    Clin Lung Cancer 7:S111-7. 2006
    ..Well-designed clinical trials with appropriate patient selection, as well as continued efforts in translational research and pharmacogenomics, are crucial for progress in this disease...
  50. doi request reprint Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    Edward S Kim
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet 372:1809-18. 2008
    ..We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy...
  51. ncbi request reprint Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA
    Clin Lung Cancer 8:195-202. 2006
    ..Further well-designed clinical trials that examine RT dose escalation, improved tumor targeting, altered fractionation, and incorporation of biologic agents are crucial for progress in this disease...
  52. ncbi request reprint Current and evolving treatment options for limited stage small cell lung cancer
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Curr Opin Oncol 18:162-72. 2006
    ..Several targeted agents have also been evaluated. This review will highlight the data that have greatly impacted on the standard of limited stage small cell lung cancer care...
  53. ncbi request reprint Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation
    Shannon K Penland
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
    Semin Radiat Oncol 14:326-34. 2004
    ..This article will review the current data regarding treatment of this heterogeneous group of patients. In addition, a brief summary of new molecular therapies and chemotherapeutics will be presented...
  54. ncbi request reprint Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Rev Recent Clin Trials 2:117-20. 2007
    ..The data from these trials suggest that optimal use of anti-angiogenic agents in NSCLC is more likely in combination with standard cytotoxic agents, however the most effective combination with the least toxicity is yet to be determined...
  55. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  56. ncbi request reprint Inter-observer reliability for the diagnosis of lung cancer in a clinical cohort using the WHO classification system, version
    J E Grilley-Olson
    University of North Carolina Chapel Hill, Chapel Hill, NC
    J Clin Oncol 26:22020. 2008
    ..This system is based on expert consensus; validation of the current version has not been well described. Using a lung cancer cohort, we estimate the reliability of the WHOC to be only moderately precise...
  57. ncbi request reprint Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing
    A Donahue
    University of North Carolina, University of Washington, CB #7360, Beard Hall, Box 357630, Chapel Hill, NC 27599-7360 Seattle, WA 98195, USA
    Cancer Chemother Pharmacol 47:373-9. 2001
    ..The greater negative bias found for the latter three estimates of carboplatin clearance could result in underdosing of carboplatin...
  58. ncbi request reprint Pemetrexed (Alimta) in small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S1-4. 2005
    ..Also, preliminary data indicates that full doses of carboplatin/pemetrexed can be administered with thoracic radiation therapy, supporting a future clinical trial initiative in LS-SCLC...
  59. ncbi request reprint The evolving role of pemetrexed (Alimta) in lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S16-22. 2005
    ..A phase II trial of single-agent pemetrexed is under way in both sensitive- and refractory-relapsed small cell lung cancer. Given the activity and excellent tolerability of pemetrexed, further studies in lung cancer are warranted...
  60. ncbi request reprint Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
    ..We designed this pharmacokinetic study to assess the ability of a fixed dose rate of gemcitabine to achieve the desired steady-state concentration in the absence and presence of paclitaxel in patients with solid tumors...
  61. ncbi request reprint Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 2:819-26. 2007
    ..Physicians' beliefs and practice patterns may differ significantly from established guidelines. We conducted a survey to assess and compare physician beliefs against the evidence-based guidelines...
  62. ncbi request reprint Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Everett E Vokes
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Clin Cancer Res 11:5045s-5050s. 2005
    ..Currently ongoing trials involving novel approaches are reviewed here...
  63. ncbi request reprint Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
    J Clin Oncol 25:1621-3. 2007
  64. doi request reprint Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
    Carrie B Lee
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina, USA
    J Thorac Oncol 4:74-9. 2009
    ..Dose escalation of radiotherapy is one strategy used to improve locoregional control and survival, but it increases the risk of both early and late treatment related toxicities...
  65. doi request reprint Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer
    M Patricia Rivera
    Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7248, USA
    Chest 135:1588-95. 2009
    ....
  66. ncbi request reprint High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial
    Julian G Rosenman
    Department of Radiation Oncology, Lineberger Comprehensive Cancer Center of the University of North Carolina University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Int J Radiat Oncol Biol Phys 54:348-56. 2002
    ..The median survival of 24 months, 3-year survival rate of 38%, and the high dose of radiation used justified a critical analysis of the technical and clinical components of this trial...
  67. doi request reprint Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 28:4769-77. 2010
    ....
  68. doi request reprint A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program at Lineberger Comprehensive Cancer Center at the University of North Carolina, Physicians Office Building, 3rd Floor 170 Manning Drive, CB 7305, Chapel Hill, NC 27599 7305, USA
    Cancer Invest 28:208-15. 2010
    ..To investigate the activity of carboplatin and cetuximab in NSCLC...
  69. ncbi request reprint Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Medical School Wing C Room 354, CB 7065, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7065, USA
    Chest 126:1656-66. 2004
    ..Further technologic improvements in PET scanners are likely to bring further benefits to the management of patients with lung cancer in the future...
  70. pmc Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:521-6. 2008
    ..This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine...
  71. ncbi request reprint Combined modality therapy for stage III non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 11:809-23. 2006
    ..Thus, continued development and participation in clinical trials is crucial to further improvements in the treatment of patients with stage III disease...
  72. ncbi request reprint Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill NC 27599 7305, USA
    Lung Cancer 52:67-74. 2006
    ..To evaluate the influence of clinical covariates, particularly pre-chemotherapy gross tumor volume (GTV), post-chemotherapy GTV, on overall survival in the treatment of stage III non-small cell lung cancer (NSCLC)...
  73. doi request reprint Current treatments for advanced stage non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Proc Am Thorac Soc 6:233-41. 2009
    ..Despite the improvements in care and number of therapeutic agents available, the survival for patients with advanced-stage NSCLC remains modest; novel approaches are required and participation in clinical trials should be encouraged...
  74. ncbi request reprint Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts
    D Neil Hayes
    University of North Carolina, Lineberger Comprehensive Cancer Center, CB 7295, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 24:5079-90. 2006
    ..Published reports suggest that DNA microarrays identify clinically meaningful subtypes of lung adenocarcinomas not recognizable by other routine tests. This report is an investigation of the reproducibility of the reported tumor subtypes...
  75. ncbi request reprint Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 24:4939-40. 2006
  76. ncbi request reprint Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Clin Oncol 24:407-12. 2006
    ..We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/III Cancer and Leukemia Group B [CALGB] trials)...
  77. doi request reprint Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008
    ..We investigate the tolerability of gefitinib in combined modality therapy in combination with three-dimensional thoracic conformal radiation therapy (3-dimensional TCRT)...
  78. doi request reprint Maintenance therapy in advanced non-small cell lung cancer: current status and future implications
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 6:174-82. 2011
    ....
  79. ncbi request reprint Molecular markers distinguish patients at differential risk of brain metastases in lung cancer by immunohistochemistry
    D N Hayes
    University of North Carolina Chapel Hill, Chapel Hill, NC University of Utah, Salt Lake City, UT
    J Clin Oncol 26:8083. 2008
    ..Predictors of brain metastasis might promote the use of PCR...
  80. ncbi request reprint Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial
    H H Gillenwater
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center and the University of North Carolina, Chapel Hill, NC, USA
    Clin Lung Cancer 2:133-8. 2000
    ..QOL was improved or maintained in over half of the patients. Given these data, gemcitabine as a single agent is a therapeutic option for patients with refractory NSCLC...
  81. ncbi request reprint Bevacizumab in the treatment of non-small-cell lung cancer
    T E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Oncogene 26:3691-8. 2007
    ..Attempts to identify surrogate markers of antiangiogenesis activity are currently ongoing, and may assist in the selection of patients for antiangiogenesis therapy and the development of this class of agents...
  82. ncbi request reprint Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts)
    N S Dhruva
    University of North Carolina, Chapel Hill, NC
    J Clin Oncol 27:e13521. 2009
    ..e13521 Background: Sorafenib had demonstrated single agent activity in non-small cell and small cell lung cancer...
  83. ncbi request reprint Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    D M Kocs
    U S Oncology, Houston, TX University of North Carolina, Chapel Hill, NC Eli Lilly and Company, Indianapolis, IN
    J Clin Oncol 26:8061. 2008
    ..In the TAX 326 trial, DCb was associated with a median survival of 11.3 mos vs. 10.1 mos for vinorelbine + C (P=.04). This open-label three-arm trial was designed to assess PCb ± ENZ versus a control arm of DCb...
  84. ncbi request reprint A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded)
    R H Ansari
    Northern Indiana Research Consortium, South Bend, IN Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC Alamance Cancer Center, Burlington, NC Highlands Oncology Group, Bentonville, AR Blood and Cancer Center of East Texas, Tyler, TX University of Oklahoma Health Sciences Center, Oklahoma City, OK sanofi aventis, Bridgewater, NJ Carle Clinic Association Cancer Center, Urbana, IL
    J Clin Oncol 26:19077. 2008
    ..This study was designed to evaluate the efficacy and tolerability of Docetaxel + Gemcitabine in combination with Bevacizumab (D/G/B) in chemotherapy-naïve Stage IIIB(non-pleural effusion)/IV NSCLC pts...
  85. ncbi request reprint Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
    M A Socinski
    University of North Carolina at Chapel Hill, Chapel Hill, NC Wake Forest University, Winston Salem, NC Yale University School of Medicine, New Haven, CT
    J Clin Oncol 27:7528. 2009
    ..7528 Background: Therapies directed at both the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways have been shown to improve survival in NSCLC and also have radiosensitizing properties...
  86. ncbi request reprint Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer
    T E Stinchcombe
    University of North Carolina at Chapel Hill, Chapel Hill, NC Alamance Cancer Center, Burlington, NC
    J Clin Oncol 26:19100. 2008
    ..Vinflunine and cetuximab may have significant activity therefore we performed a phase II trial to investigate the activity and toxicity of this combination...
  87. ncbi request reprint Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane)
    David Cella
    Center on Outcomes, Research and Education CORE, Evanston Northwestern Healthcare, and Northwestern University, Evanston, Illinois 60201, USA
    Cancer 98:822-31. 2003
    ..Cancer chemotherapy with some of the taxane class of agents can be associated with significant neurotoxicity, arthralgias, myalgias, and skin changes that may offset the therapeutic benefits of taxane use...
  88. ncbi request reprint Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Lung Cancer 51:237-43. 2006
    ....
  89. ncbi request reprint Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
    Maria Q Baggstrom
    Division of Medical Oncology, Washington University, St Louis, Missouri 63110, USA
    J Thorac Oncol 2:845-53. 2007
    ..To estimate the efficacy of third-generation (3G) chemotherapy agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) on response and survival in stage IIIB/IV non-small cell lung cancer (NSCLC)...
  90. ncbi request reprint Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer
    Rogerio Lilenbaum
    Mount Sinai Cancer Center, Miami Beach, FL 33140, USA
    J Clin Oncol 24:4825-32. 2006
    ..This multicenter, phase II, randomized trial investigated efficacy and safety of irinotecan and docetaxel and irinotecan and gemcitabine, with or without CBX, in second-line treatment of NSCLC...
  91. doi request reprint Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer
    Frank C Detterbeck
    Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut 06520 8062, USA
    J Thorac Oncol 3:37-45. 2008
    ..Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer. Two similar randomized phase II trials were conducted to define an active preoperative regimen in this disease state...
  92. doi request reprint Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901
    Stephen L Graziano
    State University of New York Upstate Medical University, Syracuse, New York 13210, USA
    J Thorac Oncol 3:158-62. 2008
    ..3 months. Because of these promising results, this dose and schedule of paclitaxel was evaluated in patients with ES-SCLC...
  93. ncbi request reprint A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 52:305-11. 2006
    ..The role of double agent therapy in this patient population is an area of investigation...
  94. doi request reprint Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
    Corey J Langer
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Thorac Oncol 3:623-30. 2008
    ....
  95. ncbi request reprint A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
    ....
  96. doi request reprint Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
    Mary E R O'Brien
    Royal Marsden Hospital, London, United Kingdom
    J Thorac Oncol 3:728-34. 2008
    ..Paclitaxel poliglumex (PPX), a macromolecular polymer-drug conjugate of paclitaxel and poly-l-glutamic acid, may enhance the therapeutic index of paclitaxel...
  97. ncbi request reprint Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, Members of the Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC, USA
    Chest 125:2300-8. 2004
    ..It is unclear and controversial whether a biopsy is needed in patients with clinical stage II lung cancer who have no PET uptake in the mediastinum...
  98. ncbi request reprint Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina at Chapel Hill, USA
    Chest 125:2294-9. 2004
    ....
  99. ncbi request reprint Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Thomas A Hensing
    Kellogg Cancer Center, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Anticancer Drugs 17:697-704. 2006
    ..The lack of activity in either patient subgroup, however, does not support further evaluation of this drug as a single agent in this disease...